Vir Biotechnology (VIR) Scheduled to Post Quarterly Earnings on Thursday

Vir Biotechnology (NASDAQ:VIR) is set to issue its quarterly earnings data after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.93) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.51. Vir Biotechnology had a negative net margin of 677.69% and a negative return on equity of 32.58%. The firm had revenue of $56.38 million during the quarter, compared to analysts’ expectations of $11.71 million. During the same quarter in the prior year, the company earned ($1.06) EPS. The company’s revenue was down 10.5% compared to the same quarter last year. On average, analysts expect Vir Biotechnology to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vir Biotechnology Stock Down 1.9 %

Shares of VIR opened at $10.50 on Tuesday. The company has a 50 day moving average price of $9.90 and a 200-day moving average price of $9.82. Vir Biotechnology has a fifty-two week low of $7.61 and a fifty-two week high of $14.27.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on VIR shares. Morgan Stanley upped their price target on shares of Vir Biotechnology from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Thursday, June 6th. JPMorgan Chase & Co. increased their target price on shares of Vir Biotechnology from $10.00 to $12.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Needham & Company LLC raised their price target on shares of Vir Biotechnology from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, June 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research note on Wednesday, June 5th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $34.00.

Insider Activity at Vir Biotechnology

In related news, Director Saira Ramasastry sold 4,000 shares of the firm’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $10.95, for a total transaction of $43,800.00. Following the sale, the director now owns 14,619 shares in the company, valued at $160,078.05. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 15.60% of the stock is owned by company insiders.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.